Wall Street brokerages predict that Axovant Sciences Ltd (NASDAQ:AXON) will report ($0.48) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Axovant Sciences’ earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.54). Axovant Sciences also reported earnings per share of ($0.48) during the same quarter last year. The business is expected to issue its next quarterly earnings results on Tuesday, February 13th.

On average, analysts expect that Axovant Sciences will report full year earnings of ($2.17) per share for the current fiscal year, with EPS estimates ranging from ($2.44) to ($1.80). For the next year, analysts anticipate that the company will report earnings of ($1.96) per share, with EPS estimates ranging from ($2.65) to ($1.22). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that follow Axovant Sciences.

Axovant Sciences (NASDAQ:AXON) last posted its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.09).

AXON has been the subject of several recent analyst reports. BidaskClub raised Axovant Sciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 23rd. Chardan Capital reissued a “sell” rating and issued a $3.00 target price on shares of Axovant Sciences in a research report on Saturday, September 23rd. Oppenheimer reissued a “buy” rating and issued a $30.00 target price on shares of Axovant Sciences in a research report on Monday, September 25th. Robert W. Baird lowered Axovant Sciences from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $29.00 to $6.00 in a research report on Tuesday, September 26th. Finally, UBS Group lowered Axovant Sciences from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 26th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $14.14.

Axovant Sciences (AXON) opened at $2.09 on Monday. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.94 and a quick ratio of 5.94. The stock has a market capitalization of $225.11, a PE ratio of -0.91 and a beta of 0.06. Axovant Sciences has a 52-week low of $2.06 and a 52-week high of $27.98.

A number of large investors have recently modified their holdings of the business. FMR LLC raised its position in Axovant Sciences by 968.5% in the 2nd quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock worth $167,794,000 after buying an additional 6,558,462 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Axovant Sciences by 21.8% during the 2nd quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock valued at $80,094,000 after purchasing an additional 619,226 shares during the period. Janus Henderson Group PLC bought a new stake in shares of Axovant Sciences during the 2nd quarter valued at about $47,854,000. OxFORD Asset Management LLP grew its stake in shares of Axovant Sciences by 842.1% during the 3rd quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock valued at $5,838,000 after purchasing an additional 777,505 shares during the period. Finally, Eagle Asset Management Inc. bought a new stake in shares of Axovant Sciences during the 3rd quarter valued at about $4,471,000. 96.93% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Brokerages Anticipate Axovant Sciences Ltd (AXON) Will Announce Earnings of -$0.48 Per Share” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/15/brokerages-anticipate-axovant-sciences-ltd-axon-will-announce-earnings-of-0-48-per-share.html.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Get a free copy of the Zacks research report on Axovant Sciences (AXON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.